

Vemurafenib BRIM-3

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Upgrade for early stopping based on interim analysis of OS

Vemurafenib BRIM-3

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Skin Cancers  
 Therapeutic Indication: As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma  
 Experimental Arm: Vemurafenib  
 Control Arm: Dacarbazine



